Athersys: Funding, Investors & Team (Oct 2026)
A clinical-stage biopharmaceutical business called Athersys has a growing pipeline of potentially best-in-class therapies that are very distinctive and intended to treat serious and life-threatening disorders. We are working to find and create novel new medications that will prolong and improve the quality of human life. We have created a pipeline of therapeutic product development programs in numerous disease areas by utilizing our patented technology. Pharmaceuticals and stem cell therapies are also part of this pathway.
Athersys has raised $17.5M across 2 funding rounds on record, the most recent an undisclosed round of $5.5M announced in Nov 2022.
That round is below the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Athersys Company Profile and Key Stats
Latest funding round on record: Nov 2022.
Athersys Funding Rounds
Athersys raised $12.0M in a Post-IPO Equity announced in Aug 2022.
3 months later, an undisclosed round of $5.5M was announced in Nov 2022.
Athersys Founders and Leadership Team
No contact details are on record for this team yet.
Athersys Funding Compared to Other Biotechnology Startups
Athersys' latest round of $5.5M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Athersys in Biotechnology and Cleveland
Companies Similar to Athersys
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Athersys Funding FAQs
What does Athersys do?
A clinical-stage biopharmaceutical business called Athersys has a growing pipeline of potentially best-in-class therapies that are very distinctive and intended to treat serious and life-threatening disorders. We are working to find and create novel new medications that will prolong and improve the quality of human life. We have created a pipeline of therapeutic product development programs in numerous disease areas by utilizing our patented technology. Pharmaceuticals and stem cell therapies are also part of this pathway.
How much funding has Athersys raised?
Athersys has raised $17.5M across 2 rounds on record. The most recent is an undisclosed round of $5.5M announced in Nov 2022.
When did Athersys last raise funding?
Athersys' most recent funding round on record is an undisclosed round of $5.5M, announced in Nov 2022.
Who is the CEO of Athersys?
William Lehmann Jr is listed as CEO at Athersys.
Where is Athersys headquartered?
Athersys is based in Cleveland, Ohio, United States.
How many employees does Athersys have?
Athersys is in the 51-100 employee band.
How does Athersys' funding compare to other Biotechnology startups?
Athersys' latest round of $5.5M is below the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Athersys Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Athersys is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.